Artificial intelligence (AI) and machine learning algorithms are transforming treatment and prognosis in hematological malignancies, as well as other areas of medicine. AI is becoming increasingly important for managing large data sets and patient information and is being explored in a number of areas. Despite the growing interest and promise of AI and machine learning algorithms in a medical setting, there are many challenges associated with applying these in a clinical setting, and questions that still need to be answered.

In this exclusive podcast, Amer Zeidan, MBBS, MHS, of Yale University and Yale Cancer Center, New Haven, CT, Aziz Nazha, MD, of the Thomas Jefferson University, Philadelphia, PA, and Anne Sophie Kubasch, MD, of Leipzig University Hospital, Leipzig, Germany, hold a fascinating discussion on the impact of artificial intelligence and machine learning in myelodysplastic syndromes (MDS).

The post The impact of AI and machine learning algorithms in MDS appeared first on VJHemOnc.